CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com
About Us
Overview
Our work in Biosimilars
Board of Directors
Executive Leadership Team
Our Stories
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Our Business
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Our Products
Global
India
Partners
Global Footprint
Our Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Investors
Newsroom
Press Releases
Company Statements
Our Stories
Media Contacts
Careers
Working With Us
Now Hiring
Contact Us
Company Statements 2022
Biocon Biologics
/
News – Posts
/
Company Statements
/
Company Statements 2022
Biocon Biologics Consolidated Statement on USFDA Inspections
Wed, 31-Aug-2022
Posted by: Biocon Biologics
No Comments
Biocon Statement on Parts of the Charge Sheet Leaked to a Media Outlet
Thu, 25-Aug-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru
Tue, 05-Jul-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics issues a statement in response to the media reports related to bribery allegations
Tue, 21-Jun-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics Denies Bribery Allegations
Tue, 21-Jun-2022
Posted by: Biocon Biologics
No Comments
The USFDA issues a complete response letter for the Biologics License Application (BLA) for insulin Aspart
Fri, 07-Jan-2022
Posted by: Biocon Biologics
No Comments
